When Does Mounjaro Peak — and What Does That Mean for Weight Loss?

What the trial data and the SmPC tell us about peak timing

The pharmacokinetic profile of tirzepatide was characterised across the SURMOUNT programme and is set out in the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC). After a subcutaneous injection, tirzepatide is absorbed gradually from the injection site, it is not an intravenous infusion, so the rise to peak concentration is gentle. Observed time-to-peak (Tmax) spans roughly 8 to 72 hours, with the distribution centred around 24 to 48 hours in the majority of participants studied. At the five-day half-life, roughly half the injected dose remains in circulation; by the time the next weekly injection is due, concentrations have declined but are far from zero. That design is deliberate. Unlike medicines with very short half-lives, tirzepatide is engineered to provide a consistent background level so the treatment effect is sustained across the full seven days. If you want to understand exactly when Mounjaro is at its peak and what drives that window, the pharmacokinetic detail is covered in full. The practical upshot: there is a genuine pharmacological peak, but the whole week is therapeutic.

Evidence from SURMOUNT-1, published in the New England Journal of Medicine, involved 2,539 adults with obesity over 72 weeks. Average body-weight reduction at the 15 mg maintenance dose reached approximately 20–21%. That outcome is cumulative across many weekly cycles, each injection contributes a peak, and the biological work done around each peak adds up over months. No single dose delivers a dramatic transformation; the trajectory builds steadily.

For anyone curious about how timing interacts with their own experience, the detail on Mounjaro's peak time window covers the pharmacokinetic data in more depth.

Why you might feel different on injection day versus day six

One of the most common questions our prescribers hear is why appetite feels noticeably suppressed in the day or two after an injection and then gradually eases toward the end of the week. The answer sits squarely in the pharmacokinetics. Appetite-suppressing signals from GIP and GLP-1 receptor activation are strongest when tirzepatide concentrations are highest, that 24–48 hour post-injection window. As levels taper through days four, five and six, some people notice hunger beginning to return, particularly before their dose is stabilised at a maintenance strength.

This is clinically normal and not a sign the medicine is failing. The gradual reduction in appetite effects toward the end of the week is sometimes called the "day-six feeling" and tends to lessen as treatment continues and steady-state concentrations build over several weeks of consistent dosing. Steady state (where weekly input matches weekly elimination) is typically reached after about four weeks of a given dose.

Nausea and other gastrointestinal effects follow a similar pattern: most pronounced in the 24 to 48 hours after injection, particularly after a dose increase, and generally settling as the body adjusts. If you keep your pen in the fridge door and inject on the same day each week, you will quickly notice your own rhythm of how those post-injection days feel compared with days five or six.

Understanding when Mounjaro's effects start to wear off through the week can help set realistic expectations around appetite and energy between doses.

How the peak relates to long-term weight loss, and why months matter more than days

The distinction between pharmacokinetic peak (concentration in the blood) and therapeutic peak (maximum weight loss achieved) is easy to blur, but they are not the same thing. Tirzepatide's plasma concentration peaks within two days of each injection. The therapeutic effect on body weight, however, accumulates over the entire treatment course.

In clinical trials, weight loss with tirzepatide continued to progress across the full 72-week study period, with no sign of plateauing at the 12- or 24-week marks where some people worry their treatment has stopped working. The starting dose (2.5 mg for the first four weeks) exists primarily so the body adjusts to the medicine rather than to produce weight loss; meaningful reduction typically begins to show from around week eight onwards as doses are titrated upward. This is worth keeping in mind if you are early in treatment and comparing weekly results. The NICE guidance on tirzepatide (TA1026) notes that if less than 5% weight loss is seen after six months at the highest tolerated dose, continuing treatment should be reviewed, a marker set against the full six-month arc, not individual injection cycles.

If you are weighing up how tirzepatide compares to semaglutide across a full treatment course, the tirzepatide information page covers the wider evidence. For questions specific to your own dosing schedule, guidance on when to take Mounjaro each week is a useful practical companion to this pharmacokinetic picture.

What the peak window means in practice, and when to seek help

Knowing that concentrations peak in the first one to two days helps explain timing, but it also shapes one practical safety point. Severe or persistent stomach pain (particularly if it radiates toward the back) that develops in the days after an injection should prompt urgent medical attention, as this can be a sign of pancreatitis, a known but uncommon side effect of GLP-1 medicines. The MHRA highlighted this risk in a Drug Safety Update in January 2026, and it is most important to act quickly if the pain does not settle within a few hours.

Other peak-window effects (nausea, reduced appetite, mild fatigue, occasional headache) are common and generally mild. Most people find them manageable and temporary. If they feel severe or do not ease after the first few weeks, speak to your prescriber rather than stopping treatment abruptly. You can also report any suspected side effects through the MHRA Yellow Card scheme.

The relationship between Mounjaro and gut conditions is worth reading if you have a pre-existing gastrointestinal condition and want to understand how the peak-day GI profile might interact with it. And if you are still in the process of deciding whether to start treatment, our clinical team (not an automated system, but actual prescribers) will review your consultation the same day. You can speak to our prescribers by starting a free consultation and get a personalised clinical view on whether Mounjaro is right for you.